However, there was a clear trend for larger improvements correlated with higher MMD at baseline (Spearman correlation coefficient −0.349, −0.340, and −0.275 for erenumab 70 mg, erenumab 140 mg, and placebo, respectively).
← all excerpts
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
1
—
—